Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of gMSC1 Versus Microfracture for Knee Cartilage Defects or Osteochondritis Dissecans
jRCT1080223548Phase 3Completed
- Sponsor
- Two Cells
- Start
- May 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gMSC1 in chondral knee defect and Osteochondritis dissecans of the knee (OCD) (2 arms), sponsored by Two Cells. Started May 2017; status: completed.
02
Drugs
gMSC1
03
Conditions
chondral knee defectOsteochondritis dissecans of the knee (OCD)
Beyond the preview
Go deeper on jRCT1080223548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223548.